Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy C4 Therapeutics (CCCC) stock

Learn how to easily invest in C4 Therapeutics stock.

C4 Therapeutics, Inc
NASDAQ: CCCC - USD
OTHER
$40.89
+$0.82 (+2.05%)

C4 Therapeutics, Inc is an other business based in the US. C4 Therapeutics shares (CCCC) are listed on the NASDAQ and all prices are listed in US Dollars. C4 Therapeutics employs 99 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in C4 Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CCCC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

C4 Therapeutics stock price (NASDAQ: CCCC)

Use our graph to track the performance of CCCC stocks over time.

C4 Therapeutics shares at a glance

Information last updated 2021-07-23.
Latest market close$36.95
52-week range$19.00 - $48.98
50-day moving average $38.99
200-day moving average $37.89
Wall St. target price$57.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy C4 Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy C4 Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

C4 Therapeutics price performance over time

Historical closes compared with the close of $36.95 from 2021-05-28

1 week (2021-07-14) N/A
1 month (2021-06-25) -2.09%
3 months (2021-04-21) N/A
6 months (2021-01-21) N/A
1 year (2020-07-21) N/A
2 years (2019-07-21) N/A
3 years (2018-07-21) N/A
5 years (2016-07-21) N/A

C4 Therapeutics financials

Revenue TTM $33.8 million
Gross profit TTM $-44,273,000
Return on assets TTM -13.89%
Return on equity TTM -57.39%
Profit margin -223.03%
Book value $6.12
Market capitalisation $1.9 billion

TTM: trailing 12 months

Shorting C4 Therapeutics shares

There are currently 2.8 million C4 Therapeutics shares held short by investors – that's known as C4 Therapeutics's "short interest". This figure is 18.5% up from 2.4 million last month.

There are a few different ways that this level of interest in shorting C4 Therapeutics shares can be evaluated.

C4 Therapeutics's "short interest ratio" (SIR)

C4 Therapeutics's "short interest ratio" (SIR) is the quantity of C4 Therapeutics shares currently shorted divided by the average quantity of C4 Therapeutics shares traded daily (recently around 723905.69948187). C4 Therapeutics's SIR currently stands at 3.86. In other words for every 100,000 C4 Therapeutics shares traded daily on the market, roughly 3860 shares are currently held short.

To gain some more context, you can compare C4 Therapeutics's short interest ratio against those of similar companies.

However C4 Therapeutics's short interest can also be evaluated against the total number of C4 Therapeutics shares, or, against the total number of tradable C4 Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case C4 Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 C4 Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0859% of the tradable shares (for every 100,000 tradable C4 Therapeutics shares, roughly 86 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against C4 Therapeutics.

Find out more about how you can short C4 Therapeutics stock.

C4 Therapeutics share dividends

We're not expecting C4 Therapeutics to pay a dividend over the next 12 months.

C4 Therapeutics overview

C4 Therapeutics, Inc. , a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.

Stocks similar to C4 Therapeutics

Frequently asked questions

What percentage of C4 Therapeutics is owned by insiders or institutions?
Currently 13.146% of C4 Therapeutics shares are held by insiders and 53.915% by institutions.
How many people work for C4 Therapeutics?
Latest data suggests 99 work at C4 Therapeutics.
When does the fiscal year end for C4 Therapeutics?
C4 Therapeutics's fiscal year ends in December.
Where is C4 Therapeutics based?
C4 Therapeutics's address is: 490 Arsenal Way, Watertown, MA, United States, 02472
What is C4 Therapeutics's ISIN number?
C4 Therapeutics's international securities identification number is: US12529R1077

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site